Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2017 /
The SOFT trial: Comparing adjuvant tamoxifen with ovarian function suppression via exemestane to tamoxifen alone

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.17
Views: 1082
Rating:

Prof Gini Fleming - University of Chicago, Chicago, USA

Dr Gini Fleming speaks with ecancer at SABCS 2017 about the outcomes of the SOFT trial comparing adjuvant tamoxifen with ovarian function suppression via exemestane to tamoxifen alone.

She describes how, after several years of treatment, differences are becoming apparent in patients who received the exemestane, with some improvement in disease free survival and overall survival.

Dr Fleming also notes the toxicities associated with treatment, summarising that for high risk  HER2 patients, this could be a treatment worth considering.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation